TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 19
Rivalry 20
LEADING COMPANIES 21
Johnson & Johnson 21
Bayer AG 26
GlaxoSmithKline Plc 31
MARKET DISTRIBUTION 36
MARKET FORECASTS 37
Market value forecast 37
MACROECONOMIC INDICATORS 38
APPENDIX 40
Methodology 40
Industry associations 41
Related Datamonitor research 41
Disclaimer 43
ABOUT DATAMONITOR 44
Premium Reports 44
Summary Reports 44
Datamonitor consulting 44
LIST OF TABLES
Table 1: Germany OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Germany OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Germany OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Germany OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Johnson & Johnson: key facts 21
Table 6: Johnson & Johnson: key financials ($) 23
Table 7: Johnson & Johnson: key financial ratios 24
Table 8: Bayer AG: key facts 26
Table 9: Bayer AG: key financials ($) 29
Table 10: Bayer AG: key financials (€) 29
Table 11: Bayer AG: key financial ratios 29
Table 12: GlaxoSmithKline Plc: key facts 31
Table 13: GlaxoSmithKline Plc: key financials ($) 33
Table 14: GlaxoSmithKline Plc: key financials (£) 34
Table 15: GlaxoSmithKline Plc: key financial ratios 34
Table 16: Germany OTC pharmaceuticals market distribution: % share, by value, 2009 36
Table 17: Germany OTC pharmaceuticals market value forecast: $ million, 2009–14 37
Table 18: Germany size of population (million), 2005–09 38
Table 19: Germany gdp (constant 2000 prices, $ billion), 2005–09 38
Table 20: Germany gdp (current prices, $ billion), 2005–09 38
Table 21: Germany inflation, 2005–09 39
Table 22: Germany consumer price index (absolute), 2005–09 39
Table 23: Germany exchange rate, 2005–09 39
LIST OF FIGURES
Figure 1: Germany OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Germany OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Germany OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Germany OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Germany, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Germany, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Germany, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Germany, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Germany, 2009 19
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Germany, 2009 20
Figure 11: Johnson & Johnson: revenues & profitability 24
Figure 12: Johnson & Johnson: assets & liabilities 25
Figure 13: Bayer AG: revenues & profitability 30
Figure 14: Bayer AG: assets & liabilities 30
Figure 15: GlaxoSmithKline Plc: revenues & profitability 35
Figure 16: GlaxoSmithKline Plc: assets & liabilities 35
Figure 17: Germany OTC pharmaceuticals market distribution: % share, by value, 2009 36
Figure 18: Germany OTC pharmaceuticals market value forecast: $ million, 2009–14 37
[Fade out table of contents]
